Standard
The IMPACT Trial : Single Inhaler Triple Therapy vs dual therapies. Consistent benefit across multiple exacerbation endpoints. / Han, MeiLan K.; Criner, Gerard; Dransfield, Mark; Halpin, David; Jones, C. Elaine; Kilbride, Sally; Lange, Peter; Lomas, David; Martinez, Fernando; Quasny, Holly; Singh, David; Wise, Robert; Lipson, David.
I:
European Respiratory Journal, Bind 54, Nr. Supplement 63, PA2483, 2019.
Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › fagfællebedømt
Harvard
Han, MK, Criner, G, Dransfield, M, Halpin, D, Jones, CE, Kilbride, S
, Lange, P, Lomas, D, Martinez, F, Quasny, H, Singh, D, Wise, R & Lipson, D 2019, '
The IMPACT Trial: Single Inhaler Triple Therapy vs dual therapies. Consistent benefit across multiple exacerbation endpoints',
European Respiratory Journal, bind 54, nr. Supplement 63, PA2483.
https://doi.org/10.1183/13993003.congress-2019.PA2483APA
Han, M. K., Criner, G., Dransfield, M., Halpin, D., Jones, C. E., Kilbride, S.
, Lange, P., Lomas, D., Martinez, F., Quasny, H., Singh, D., Wise, R., & Lipson, D. (2019).
The IMPACT Trial: Single Inhaler Triple Therapy vs dual therapies. Consistent benefit across multiple exacerbation endpoints.
European Respiratory Journal,
54(Supplement 63), [PA2483].
https://doi.org/10.1183/13993003.congress-2019.PA2483Vancouver
Han MK, Criner G, Dransfield M, Halpin D, Jones CE, Kilbride S o.a.
The IMPACT Trial: Single Inhaler Triple Therapy vs dual therapies. Consistent benefit across multiple exacerbation endpoints.
European Respiratory Journal. 2019;54(Supplement 63). PA2483.
https://doi.org/10.1183/13993003.congress-2019.PA2483Author
Han, MeiLan K. ; Criner, Gerard ; Dransfield, Mark ; Halpin, David ; Jones, C. Elaine ; Kilbride, Sally ; Lange, Peter ; Lomas, David ; Martinez, Fernando ; Quasny, Holly ; Singh, David ; Wise, Robert ; Lipson, David. / The IMPACT Trial : Single Inhaler Triple Therapy vs dual therapies. Consistent benefit across multiple exacerbation endpoints. I: European Respiratory Journal. 2019 ; Bind 54, Nr. Supplement 63.
Bibtex
@article{91d39a9c15bb495ca9c3b1206ba1563c,
title = "The IMPACT Trial: Single Inhaler Triple Therapy vs dual therapies. Consistent benefit across multiple exacerbation endpoints",
keywords = "COPD - exacerbations, COPD - management",
author = "Han, {MeiLan K.} and Gerard Criner and Mark Dransfield and David Halpin and Jones, {C. Elaine} and Sally Kilbride and Peter Lange and David Lomas and Fernando Martinez and Holly Quasny and David Singh and Robert Wise and David Lipson",
year = "2019",
doi = "10.1183/13993003.congress-2019.PA2483",
language = "English",
volume = "54",
journal = "The European Respiratory Journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "Supplement 63",
}
RIS
TY - ABST
T1 - The IMPACT Trial
T2 - Single Inhaler Triple Therapy vs dual therapies. Consistent benefit across multiple exacerbation endpoints
AU - Han, MeiLan K.
AU - Criner, Gerard
AU - Dransfield, Mark
AU - Halpin, David
AU - Jones, C. Elaine
AU - Kilbride, Sally
AU - Lange, Peter
AU - Lomas, David
AU - Martinez, Fernando
AU - Quasny, Holly
AU - Singh, David
AU - Wise, Robert
AU - Lipson, David
PY - 2019
Y1 - 2019
KW - COPD - exacerbations
KW - COPD - management
U2 - 10.1183/13993003.congress-2019.PA2483
DO - 10.1183/13993003.congress-2019.PA2483
M3 - Conference abstract in journal
VL - 54
JO - The European Respiratory Journal
JF - The European Respiratory Journal
SN - 0903-1936
IS - Supplement 63
M1 - PA2483
ER -
